- Home
- ITRM vs ANTX Comparison
ITRM vs ANTX Comparison
Compare ITRM & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- ANTX
- Stock Information
- Founded
- ITRM 2015
- ANTX 2017
- Country
- ITRM Ireland
- ANTX United States
- Employees
- ITRM N/A
- ANTX N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- ITRM Health Care
- ANTX Health Care
- Exchange
- ITRM Nasdaq
- ANTX Nasdaq
- Market Cap
- ITRM 40.0M
- ANTX 33.2M
- IPO Year
- ITRM 2018
- ANTX 2022
- Fundamental
- Price
- ITRM $0.82
- ANTX $1.08
- Analyst Decision
- ITRM Strong Buy
- ANTX Buy
- Analyst Count
- ITRM 2
- ANTX 2
- Target Price
- ITRM $7.00
- ANTX $2.00
- AVG Volume (30 Days)
- ITRM 751.2K
- ANTX 73.9K
- Earning Date
- ITRM 08-13-2025
- ANTX 08-12-2025
- Dividend Yield
- ITRM N/A
- ANTX N/A
- EPS Growth
- ITRM N/A
- ANTX N/A
- EPS
- ITRM N/A
- ANTX N/A
- Revenue
- ITRM N/A
- ANTX N/A
- Revenue This Year
- ITRM N/A
- ANTX N/A
- Revenue Next Year
- ITRM $270.19
- ANTX N/A
- P/E Ratio
- ITRM N/A
- ANTX N/A
- Revenue Growth
- ITRM N/A
- ANTX N/A
- 52 Week Low
- ITRM $0.81
- ANTX $0.87
- 52 Week High
- ITRM $3.02
- ANTX $2.74
- Technical
- Relative Strength Index (RSI)
- ITRM 35.21
- ANTX 53.78
- Support Level
- ITRM $0.81
- ANTX $1.05
- Resistance Level
- ITRM $0.90
- ANTX $1.16
- Average True Range (ATR)
- ITRM 0.08
- ANTX 0.03
- MACD
- ITRM -0.02
- ANTX 0.01
- Stochastic Oscillator
- ITRM 4.46
- ANTX 66.04
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.